Bone morphogenetic protein-2 (BMP-2) is an osteoinductive growth factor used clinically to induce bone regeneration and fusion. Some complications associated with BMP-2 treatment have been attributed to rapid release of BMP-2 from conventional collagen scaffolds, motivating the development of tunable sustained-release strategies. We incorporated BMP-2-binding heparin microparticles (HMPs) into a hydrogel scaffold to improve spatiotemporal control of BMP-2 delivery to large bone defects. HMPs pre-loaded with BMP-2 were mixed into alginate hydrogels and compared to hydrogels containing BMP-2 alone. BMP-2 release from scaffolds in vitro, BMP-2 retention within injury sites in vivo, and bone regeneration in a critically sized femoral defect wer...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic proteins (BMPs) are the most potent osteoinductive growth factors. However, a del...
\u3cp\u3eThe aim of the current study was to reduce the clinically used supra-physiological dose of ...
Bone morphogenetic protein-2 (BMP-2) is an osteoinductive growth factor used clinically to induce bo...
Supraphysiologic doses of bone morphogenetic protein-2 (BMP-2) are used clinically to promote bone f...
Despite the glimmer of hope provided by the discovery and commercialization of bone morphogenetic pr...
<div><p>Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of...
Although bone morphogenetic protein-2 (BMP-2) is known to be the most potent stimulator available fo...
Summary Growth factor-based therapies have been shown to facilitate bone tissue engineering. Bone mo...
Tissue engineering strategies involving the in vivo delivery of recombinant growth factors are often...
Tissue engineering strategies involving the in vivo delivery of recombinant growth factors are often...
Tissue engineering strategies involving the in vivo delivery of recombinant growth factors are often...
This thesis investigated hybrid biomaterial systems with controlled strategies for bone morphogeneti...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic proteins (BMPs) are the most potent osteoinductive growth factors. However, a del...
\u3cp\u3eThe aim of the current study was to reduce the clinically used supra-physiological dose of ...
Bone morphogenetic protein-2 (BMP-2) is an osteoinductive growth factor used clinically to induce bo...
Supraphysiologic doses of bone morphogenetic protein-2 (BMP-2) are used clinically to promote bone f...
Despite the glimmer of hope provided by the discovery and commercialization of bone morphogenetic pr...
<div><p>Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of...
Although bone morphogenetic protein-2 (BMP-2) is known to be the most potent stimulator available fo...
Summary Growth factor-based therapies have been shown to facilitate bone tissue engineering. Bone mo...
Tissue engineering strategies involving the in vivo delivery of recombinant growth factors are often...
Tissue engineering strategies involving the in vivo delivery of recombinant growth factors are often...
Tissue engineering strategies involving the in vivo delivery of recombinant growth factors are often...
This thesis investigated hybrid biomaterial systems with controlled strategies for bone morphogeneti...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeleta...
Bone morphogenetic proteins (BMPs) are the most potent osteoinductive growth factors. However, a del...
\u3cp\u3eThe aim of the current study was to reduce the clinically used supra-physiological dose of ...